Apellis Pharmaceuticals Inc

NASDAQ:APLS   3:59:59 PM EDT
60.70
-4.20 (-6.47%)
Products, Regulatory

Swedish Orphan Biovitrum- Positive Top-Line Results From Phase 3 Prince Study Of Pegcetacoplan In Treatment-Naïve Patients With PNH

Published: 05/25/2021 12:53 GMT
Apellis Pharmaceuticals Inc (APLS) - Swedish Orphan Biovitrum -.
Positive Top-line Results From Phase 3 Prince Study of Pegcetacoplan in Treatment-naÏve Patients With Pnh.
Swedish Orphan Biovitrum - Pegcetacoplan Demonstrated Statistical Superiority on Co-primary Endpoints.
Swedish Orphan Biovitrum - 91% of Patients on Pegcetacoplan Were Transfusion Free Compared to 22% on Standard of Care.
Swedish Orphan Biovitrum - Safety Profile of Pegcetacoplan Was Consistent With Previous Studies.